Less than 1 min.Read

C2i Genomics: Raises $100M in Funding

April 17, 2021

C2i Genomics, a New York, NY-based cancer intelligence company, raised $100m in financing
The round was led by Casdin Capital with participation from NFX, Duquesne Family Office, Section 32, iGlobe Partners, Driehaus Capital and others
The financing was executed as a convertible note with two tranches of $50m, called by the company with additional participation from The Mark Foundation for Cancer Research, Silver Lake
The company intends to use the funds to accelerate clinical development and commercialization of its C2-Intelligence Platform and to deepen its partnerships with pharmaceutical companies
C2i provides a cloud-based cancer diagnostics service that uses AI pattern recognition and whole-genome analysis to provide rapid and accurate detection of residual disease
With the platform, physicians can spot trace amounts of persistent or recurrent cancer much earlier, at far lower levels, to inform treatment decisions